NCT03200977View on ClinicalTrials.gov

Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab

CompletedOBSERVATIONAL
Enrollment

95

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

June 3, 2022

Study Completion Date

June 3, 2022

Conditions
Lymphoma
Interventions
OTHER

Non-Interventional

Non-Interventional

Trial Locations (2)

53226

Center for International Blood and Marrow Transplant Research, Milwaukee

08543

Local Institution - 0001, Lawrenceville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY